Relieving the Weight: Fenfluramine’s Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280251396957 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Simone A McCay und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic Arizona Hospital, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Fenfluramine, Lennox Gastaut Syndrome, Epilepsies, Myoclonic, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objective
To review the pharmacology, usage, efficacy, and safety of fenfluramine in treating seizures in pediatric patients with Lennox-Gastaut syndrome or Dravet syndrome. Data sources: The PubMed database was searched for studies using the search terms “Lennox-Gastaut Syndrome,” “Dravet Syndrome,” “fenfluramine,” and “Fintepla©.” Study selection and data extraction: Articles were selected based on the following criteria: published in English, published between January 1950 and September 2025, and included clinical relevancy for pharmacology, efficacy, and adverse events. Data synthesis: In a phase 3 trial, patients with Lennox-Gastaut syndrome experienced a median 26.5% decrease in frequency of drop seizures when taking the 0.7 mg/kg/d dose. In a 2-part phase 2 trial, 54% of patients with Dravet syndrome concurrently taking stiripentol experienced a >50% decrease in monthly seizures at a dosage of 0.4 mg/kg/d; 72.9% of patients with Dravet syndrome not concurrently taking stiripentol experienced a >50% decrease in monthly seizures at a dosage of 0.7 mg/kg/d. Most common adverse effects in both trials included lethargy, decreased weight, and decreased appetite. Relevance to patient care and clinical practice: Fenfluramine’s dual mechanism of action makes it uniquely suited to reduce seizure activity after previous failures in treatment. Some providers are hesitant to prescribe fenfluramine due to its historical association with severe cardiovascular risks. However, proper dosage and titration, as well as adherence to the Risk Evaluation and Mitigation Strategy program can sufficiently mitigate risk for the outcome of seizure reduction and increased quality of life.
Conclusions
As seen through the results of multiple clinical trials, fenfluramine can provide significant seizure reduction for Lennox-Gastaut and Dravet patients with treatment-resistant seizures. Risks can be mitigated through adherence to proper programs and schedules, and can provide enough benefits to outweigh risks in patients with particularly resistant epilepsies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic Arizona Hospital, Phoenix, AZ, USA.
- Department of Pharmacy, Mayo Clinic Arizona Hospital, Phoenix, AZ, USA.
ORCID-Profile: Simone A McCay
Zitieren
APA
McCay, S. A., Shiue, H. J., & Hoerth, M. T. (2025). Relieving the Weight: Fenfluramine’s Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251396957
Vancouver
McCay SA, Shiue HJ, Hoerth MT. Relieving the Weight: Fenfluramine’s Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251396957
BibTeX
@article{McCay2025,
author = {McCay, Simone A and Shiue, Harn J and Hoerth, Matthew T},
title = {Relieving the Weight: Fenfluramine’s Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280251396957}
}
EUVIMED